Sabarubicin
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC32H37NO13
Molar mass643.642 g·mol−1
3D model (JSmol)
  • C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@@H](O[C@H](C[C@@H]2O)O[C@H]3C[C@@](Cc4c3c(c5c(c4O)C(=O)c6ccccc6C5=O)O)(C(=O)CO)O)C)N)O
  • InChI=InChI=1S/C32H37NO13/c1-12-26(37)17(33)7-21(43-12)46-31-13(2)44-22(8-18(31)35)45-19-10-32(42,20(36)11-34)9-16-23(19)30(41)25-24(29(16)40)27(38)14-5-3-4-6-15(14)28(25)39/h3-6,12-13,17-19,21-22,26,31,34-35,37,40-42H,7-11,33H2,1-2H3/t12-,13-,17-,18-,19-,21-,22-,26+,31-,32-/m0/s1

Sabarubicin (MEN-10755), a disaccharide analog of doxorubicin, is used for the treatment of small cell lung cancer (SCLC).[1] It has been seen to show superior antitumour efficacy, which is purported to be linked to the activation of p53-independent apoptosis[2]

References

  1. ↑ Committee for Orphan Medicinal Products (6 October 2009). "Public summary of positive opinion for orphan designation of sabarubicin for the treatment of small cell lung cancer" (PDF). European Medicines Agency.
  2. ↑ Arcamone FM (2008). "Sabarubicin". Topics in Current Chemistry. 283: 171–89. doi:10.1007/128_2007_1. PMID 23605632.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.